Ascendis制药 ASND 深 沪
等待开盘 03-26 09:30:00 美东时间
220.43
+4.890
+2.27%
华盛通- 最 高222.975
- 今 开216.57
- 成交量 22.46万股
- 最 低 216.135
- 昨 收 215.54
- 总市值 136.62亿
- 52周最高 248.60
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 124.06
- 委 比 -63.93%
- 总股本 6197.74万
- 历史最高 248.60
- 量 比 0.58
- 振 幅 3.17%
- 历史最低 11.92
- 每 手 1
- 风险率 24.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
BioMarin stops mid-stage trials of bone disorder treatment
BioMarin stops mid-stage trials of bone disorder treatment March 16 (Reuters) - BioMarin Pharmaceutical BMRN.O will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker said on Monday, sending its share
03-16 21:34
Ascendis Pharma Announces Data From Pivotal ApproaCH Trial Showing Children With Achondroplasia Treated With Once-Weekly TransCon CNP Maintained Consistent Improvements In Growth Through Week 104, With Further Improvement In Body Proportionality During Second Year Of Treatment
Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent
03-16 20:06
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Ascendis Pharma Receives FDA Approval For YUVIWEL For Children With Achondroplasia Aged 2 Years and Older; Commercial Availability Expected During Early Part Of Q2 2026; Rare Pediatric Disease Priority Review Voucher Granted In Connection With Approval
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease
02-28 07:03
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
Ascendis Pharma's YUVIWEL, the first weekly treatment for achondroplasia, received FDA approval under the Accelerated Approval Program. It provides continuous systemic exposure to CNP over weekly dosing. YUVIWEL is indicated for children 2 years and older with open epiphyses. Commercial availability is expected in early Q2 2026. A Rare Pediatric Disease Priority Review Voucher was granted. Ascendis will host an investor call on March 2 to discuss...
02-27 22:57
Ascendis Pharma A/S Announces Annual General Meeting
Ascendis Pharma A/S Announces Annual General Meeting Ascendis Pharma A/S will hold its annual general meeting on March 23, 2026 in Copenhagen, Denmark. Shareholders will vote on the election of the chair of the meeting; a report on the company’s activities during the past year; approval of the audit
02-24 05:08
美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元
02-13 15:30
电话会总结 ｜ Ascendis Pharma(ASND)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Ascendis Pharma 2025年第四季度及全年业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年全年总营收：7.2亿欧元 - Q4营收：2.48亿欧元（包含700万欧元合作收入） - Yorvipath产品：Q4营收1.87亿欧元，全年营收4.77亿欧元 - Skytrofa产品：Q4营收5300万欧元，全年营收2.06亿欧元 **盈利能力：** - Q4经营利润：1000万欧元 - 全年经营费用：7.61亿欧元 - Q4经营费用：2.14亿欧元 **现金流状况：** - Q4经营现金流：73
02-12 12:17
